Search Results for "Crth2 Allergic Rhinitis"
Original Source: The prostaglandin D(2) receptor CRTH2 is important for allergic skin inflammation after epicutaneous antigen challenge.
BACKGROUND: Cutaneous prostaglandin (PG) D(2) levels increase after scratching. Chemoattractant receptor-homologous molecule expressed on receptor on T(H)2 cells (CRTH2) mediates chemotaxis to PGD(2) and is expressed on T(H)2 cells and eosinophils, which infiltrate skin lesions in patients with atopic dermatitis. OBJECTIVE: We sought to examine the role of CRTH2 in a murine model of atopic dermatitis. METHODS: CRTH2(-/-) mice and wild-type control animals were epicutaneously sensitized by means of repeated...
Matching Channels
Matching News
Allergic Rhinitis Partnering 2007-2012
The Allergic Rhinitis Partnering 2007-2012 provides understanding and access to the allergic rhinitis partnering deals and agreements entered into by the worlds leading healthcare companies. The rep...
Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis
Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay feve...
Study examines prevalence of local allergic rhinitis
(HealthDay)—Local allergic rhinitis (LAR) is prevalent among patients with rhinitis, affecting about one in four, and is often associated with childhood onset and persistent, severe conjunctivitis a...
Correlation of Symptoms With IgE in Allergic Rhinitis
Differentiation of allergic rhinitis from other etiologic-based rhinitis is frequently difficult. Will IgE make it easy? Therapeutic Advances in Respiratory Disease
FDA OKs Karbinal ER for Allergic Rhinitis in Children
The sustained-release antihistamine is indicated for the treatment of seasonal and perennial allergic rhinitis in children aged 2 years and older. FDA Approvals
FDA OKs Carbinoxamine ER for Allergic Rhinitis in Children
The sustained-release antihistamine is indicated for the treatment of seasonal and perennial allergic rhinitis in children aged 2 years and older. FDA Approvals
Meda's Dymista approved for allergic rhinitis
Meda AB (SSE:MEDAA) said its Dymista azelastine/fluticasone was approved under the EU's decentralized procedure to treat seasonal and perennial allergic rhinitis. Germany acted as the reference member...
Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert
Allergic rhinitis is most commonly recognized as hay fever in the United Kingdom and it is due to the impact of an allergen, in the case of hay fever a pollen, setting off an inflammatory response in...
Matching PubMed Articles
BACKGROUND: CRTh2 (chemoattractant-receptor homologous molecule expressed on Th2 cells) is expressed by Th2 cells and other cells involved in allergic inflammation. Single nucleotide polymorphisms (SN...
Novel CRTH2 antagonists: a review of patents from 2006 to 2009.
Importance of the field: The receptor CRTH2 (also known as DP(2)) is an important mediator of the inflammatory effects of prostaglandin D(2) and has attracted much attention as a therapeutic target fo...
The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice.
CD30 ligand (CD30L) plays important role in the amplification and/or activation of effector CD4(+) T cells, irrespective of Th cell subset. To examine the role of CD30L in allergic rhinitis, we evalua...
Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety.
Sublingual immunotherapy (SLIT) is now an established treatment for allergic rhinitis. Whilst several systematic reviews have now confirmed clinical efficacy and safety, recent analysis also confirms...
Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.
Context: The role of ceruloplasmin oxidase activity (COA) involving the interaction of oxidant and antioxidant balance in allergic diseases is still unknown. Objective: Our study was designed to exami...
